The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Factors affecting PS deterioration at the time of relapse after the first-line EGFR-TKI therapy in EGFR-mutant advanced NSCLC.
Tomoki Tamura
No relevant relationships to disclose
Katsuyuki Hotta
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma
Hiroko Gotoda
No relevant relationships to disclose
Yuka Kato
No relevant relationships to disclose
Eiki Ichihara
No relevant relationships to disclose
Toshio Kubo
No relevant relationships to disclose
Mitsune Tanimoto
No relevant relationships to disclose
Katsuyuki Kiura
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma